Vertex Pharma stock stands at EUR 449.93 with USD 128.1 billion market cap

Published on 10/08/2026 at 19:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharma stock costs EUR 449.93 on October 8, 2026, versus EUR 451.65. Nasdaq P/E is 29.40.

Key points in brief

Vertex Pharma stock stood at EUR 449.93 at Lang & Schwarz on October 8, 2026 at 7:41 p.m. CEST, minus 0.38 percent versus EUR 451.65.
The Nasdaq-listed company had a USD 128.1 billion market capitalization and a P/E ratio of 29.40.
The next earnings report is scheduled for November 2, 2026, after the financial markets close.
Regeneron Pharmaceuticals fell 0.56 percent and Gilead Sciences fell 0.40 percent in the same market snapshot.

Trading-Floor mit Händlern vor großen Bildschirmen und biotechnischen Chart-Visualisierungen — Vertex Pharma US92532F1003 zeigt einen Börsen-Trading-Floor mit Biotech-Charts und stilisierter Molekül-Datenvisualisierung im Hintergrund, Illustration mit AI erstellt.

Vertex Pharma stock stood at EUR 449.93 at Lang & Schwarz on October 8, 2026 at 7:41 p.m. CEST, down 0.38 percent versus the EUR 451.65 prior close. The Nasdaq-listed biotechnology company had a USD 128.1 billion market capitalization, while its primary-exchange quote was USD 504.81 at 1:50 p.m. ET.

Price remains below yearly high

The Nasdaq quote was 9.90 percent below the 52-week high of USD 560.25 and 25.36 percent above the 52-week low of USD 402.58 on October 8, 2026. The same quote carried a P/E ratio of 29.40, putting valuation alongside the stock's position within its annual range.

Vertex's euro quotation was lower than the Nasdaq reference in the available session snapshot, but the two values represent different venues and currencies. For German investors, the Lang & Schwarz price and its EUR 451.65 prior close remain the relevant daily comparison.

Analyst target reaches USD 665

Markets Insider reported on October 7, 2026 that Morgan Stanley analyst Terence Flynn assigned a Buy rating and a USD 665.00 price target. Relative to the USD 504.81 Nasdaq quote, that target stood 31.73 percent higher, a separate valuation reference from the P/E ratio.

Next report is November 2

Vertex Pharmaceuticals said on October 7, 2026 that it will report third-quarter 2026 financial results on November 2, 2026, after the financial markets close, followed by a conference call at 4:30 p.m. ET. That calendar date gives the next scheduled point for a fresh operating update.

Comparison with peers

Vertex Pharma: minus 0.38 percent, P/E 29.40, market capitalization USD 128.1 billion

Regeneron Pharmaceuticals (Nasdaq, USD): minus 0.56 percent, P/E 18.25, market capitalization USD 76.0 billion

Gilead Sciences (Nasdaq, USD): minus 0.40 percent, P/E minus 54.79, market capitalization USD 181.4 billion

Trading snapshot

Vertex Pharma stock was trading at EUR 449.93 at Lang & Schwarz on October 8, 2026 at 7:41 p.m. CEST, minus 0.38 percent versus the prior close of EUR 451.65 from October 7, 2026. The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.